Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
vopimetostat · 1 trial · 8 indications
To determine the MTD and RD(s) of vopimetostat in combination with ERAS-0015
To assess antitumor activity- ORR of vopimetostat in combination with ERAS-0015
| Arm | Type | Description |
|---|---|---|
| Dose Escalation PDAC | EXPERIMENTAL | Escalating doses of vopimetostat in combination with ERAS-0015 |
| Dose expansion 1L PDAC | EXPERIMENTAL | Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015 |
| Dose Expansion 2L PDAC | EXPERIMENTAL | Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015 |
| Dose Expansion 2L or 3L NSCLC | EXPERIMENTAL | Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015 |
| Name | Type | Description |
|---|---|---|
| vopimetostat | DRUG | MTA-cooperative PRMT5 inhibitor |
| ERAS-0015 | DRUG | Pan-RAS molecular glue |
Inclusion Criteria: 1. Is ≥18 years of age at the time of signature of the main study ICF. 2. Has an ECOG PS of 0 or 1. 3. Has loss of the MTAP gene, documented by a validated assay 4. Has one of the following disease characteristics: * 1L or 2L metastatic PDAC * Locally advanced, recurrent ...